Population Pharmacokinetics of Candesartan in Patients with Chronic Heart Failure

Research Publications | 1 Minute Read

Imad Kassem 1 2, Steven Sanche 1, Jun Li 1 3, Guillaume Bonnefois 4, Marie-Pierre Dubé 2 5 6, Jean-Lucien Rouleau 2 5, Jean-Claude Tardif 2 5 6, Michel White 2 5, Jacques Turgeon 7, Fahima Nekka 1 3, Simon de Denus 1 2 6


Heart failure (HF) causes pathological changes in multiple organs, thus affecting the pharmacokinetics (PK) of drugs. The aim of this study was to investigate the PK of candesartan in patients with HF while examining significant covariates and their related impact on estimated clearance using a population PK (Pop-PK) modeling approach. Data from a prospective, multicenter study were used. Modeling and simulations were conducted using Nonlinear Mixed-Effects Modeling (NONMEM) and R software. A total of 281 white patients were included to develop the Pop-PK model. The final model developed for apparent oral clearance (CL/F) included weight, estimated glomerular filtration rate (eGFR), and diabetes, which partly explained its interindividual variability. The mean CL/F value estimated was 7.6 L/h (1.7-22.6 L/h). Simulations revealed that an important decrease in CL/F (> 25%) is obtained with the combination of the factors retained in the final model. Considering these factors, a more individualized approach of candesartan dosing should be investigated in patients with HF.

Share this:
Fill 1 Copy 2closeFill 5 Copy 4green-arrowhamburgerFill 7 Copy 4Fill 1 Copy 4pauseplaysearch-iconFill 3 Copy 4